<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Low anterior resection syndrome (LARS)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Low anterior resection syndrome (LARS)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Low anterior resection syndrome (LARS)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jacopo Martellucci, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin Weiser, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Wenliang Chen, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2196725144"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Surgery is the only curative therapy for rectal cancer. Transabdominal surgery can be performed with either sphincter-sparing techniques (ie, anterior resection) or an abdominal perineal resection. Historically, abdominoperineal resection was the gold standard for treating low-lying rectal cancers. With the advent of better surgical techniques and equipment (eg, staplers) as well as neoadjuvant therapy, abdominoperineal resection has been gradually replaced by sphincter-sparing procedures. For patients in whom a negative distal margin can be achieved, sphincter-sparing procedures are preferred because they maintain bowel continence and avoid a permanent colostomy. In contemporary practices, sphincter-sparing procedures are feasible in up to 80 percent of patients requiring surgery for rectal cancer.</p><p>However, functional disturbances constitute a major problem for many surviving rectal cancer patients following a sphincter-sparing procedure, with symptoms ranging from daily episodes of incontinence to obstructed defecation and constipation. Although such symptoms have an immense impact on the patient's quality of life, there is presently no specific treatment. Instead, management is empirical and symptom based, using existing therapies for fecal incontinence, fecal urgency, and rectal evacuatory disorders.</p><p>In this topic, we discuss the clinical manifestations, diagnosis, and treatment of bowel symptoms that develop following sphincter-sparing resections of the rectum. Such symptoms have been collectively referred to as low anterior resection syndrome (LARS). The techniques of sphincter-sparing resection and the treatment of fecal incontinence, urgency, or other rectal evacuatory disorders of the gastrointestinal tract not necessarily related to surgery are discussed separately. (See  <a class="medical medical_review" href="/d/html/15311.html" rel="external">"Surgical treatment of rectal cancer"</a> and  <a class="medical medical_review" href="/d/html/96913.html" rel="external">"Fecal incontinence in adults: Management"</a> and  <a class="medical medical_review" href="/d/html/2636.html" rel="external">"Management of chronic constipation in adults"</a>.)</p><p class="headingAnchor" id="H3233639179"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>LARS is defined by at least one of the following symptoms resulting in at least one of the following consequences that occur after a sphincter-sparing resection (ie, anterior resection) of the rectum [<a href="#rid1">1</a>]:</p><p>Symptoms:</p><p class="bulletIndent1"><span class="glyph">●</span>Variable, unpredictable bowel function</p><p class="bulletIndent1"><span class="glyph">●</span>Altered stool consistency</p><p class="bulletIndent1"><span class="glyph">●</span>Increased stool frequency</p><p class="bulletIndent1"><span class="glyph">●</span>Repeated painful stools</p><p class="bulletIndent1"><span class="glyph">●</span>Emptying difficulties</p><p class="bulletIndent1"><span class="glyph">●</span>Urgency</p><p class="bulletIndent1"><span class="glyph">●</span>Incontinence</p><p class="bulletIndent1"><span class="glyph">●</span>Soiling</p><p></p><p>Consequences:</p><p class="bulletIndent1"><span class="glyph">●</span>Toilet dependence</p><p class="bulletIndent1"><span class="glyph">●</span>Preoccupation with bowel function</p><p class="bulletIndent1"><span class="glyph">●</span>Dissatisfaction with bowels</p><p class="bulletIndent1"><span class="glyph">●</span>Strategies and compromises</p><p class="bulletIndent1"><span class="glyph">●</span>Impact on mental and emotional wellbeing</p><p class="bulletIndent1"><span class="glyph">●</span>Impact on social and daily activities</p><p class="bulletIndent1"><span class="glyph">●</span>Relationships and intimacy</p><p class="bulletIndent1"><span class="glyph">●</span>Roles, commitments, and responsibilities</p><p></p><p class="headingAnchor" id="H315148059"><span class="h1">EPIDEMIOLOGY AND RISK FACTORS</span><span class="headingEndMark"> — </span>According to a 2021 systematic review and meta-analysis of 50 studies, the pooled incidence of major LARS is 44 percent (95% CI 40 to 48 percent) [<a href="#rid2">2</a>]. About 50 percent of patients still report symptoms more than 10 years after surgery [<a href="#rid3">3,4</a>]. For individual patients, symptoms vary in type, severity, and duration as a reflection of different underlying etiologies. </p><p>Potential risk factors for LARS include [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Long-course neoadjuvant radiotherapy (odds ratio [OR] 2.89, 95% CI 2.06–4.05) [<a href="#rid5">5-7</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Total mesorectal excision (TME) (OR 2.13, 95% CI 1.49–3.04)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anastomotic leak (OR 1.98, 95% CI 1.34–2.93)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diverting stoma (OR 1.89, 95% CI 1.58–2.27)</p><p></p><p>No significant difference in postoperative anorectal dysfunction has been observed between open and laparoscopic TME [<a href="#rid8">8</a>]. Pouch reconstruction was not found to be significantly beneficial to anorectal functions in long term.</p><p>Among these potential risk factors, pelvic radiotherapy is consistently associated with LARS, regardless of the timing of administration (neoadjuvant versus adjuvant) [<a href="#rid5">5,6</a>]. By contrast, neoadjuvant chemotherapy, whether administered alone or added to chemoradiation therapy, did not seem to impair bowel function [<a href="#rid7">7</a>].</p><p>The presence of defunctioning stoma seems to have a negative impact on functional bowel activity after low rectal resection, in particular for delayed closure (&gt;90 days) and for ileostomy. This should be considered when the type of stoma (ileostomy versus colostomy) is selected for each patient [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H2340883225"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>Symptoms of LARS are usually caused by a combination of colonic dysmotility, neorectal reservoir dysfunction, and anal sphincter dysfunction.</p><p class="headingAnchor" id="H1667982169"><span class="h2">Colonic dysmotility</span><span class="headingEndMark"> — </span>LARS can be caused by increased proximal colonic motility coupled with a lack of distal inhibition in patients who undergo sphincter-sparing resections. </p><p>There is evidence that denervation of the remnant sigmoid colon [<a href="#rid10">10</a>] or left colon [<a href="#rid11">11</a>] by operative maneuvers (eg, ligation of a vascular pedicle) can result in a significant increase in motility. As a result, patients with LARS have a shorter colonic transit time [<a href="#rid12">12,13</a>] and a greater increase in neorectal pressure after a meal compared with patients who do not have LARS [<a href="#rid14">14</a>]. </p><p>Removal of the rectum and in particular the rectosigmoid junction eliminates the physiologic distal control center for the regulation of bowel transit, leaving the bowel activities without a "brake." This lack of distal negative feedback signals to oppose increased proximal colonic motility further exacerbates the symptoms of LARS.</p><p class="headingAnchor" id="H1206996228"><span class="h2">Neorectal reservoir dysfunction</span><span class="headingEndMark"> — </span>Two aspects of neorectal reservoir dysfunction, denervation and reduction in functional capacity, both contribute to LARS symptoms.</p><p>The remnant rectum or neorectum may be denervated by surgical dissection or pelvic radiotherapy. A denervated neorectum is hyposensitive to mechanical and thermal stimuli due to impaired afferent nerve function [<a href="#rid15">15</a>] and is thus susceptible to causing LARS symptoms. There is evidence that the risk of LARS is greater after total as opposed to partial mesorectal excision and after neoadjuvant therapy. </p><p>Besides denervation, the neorectal function may also be compromised by a reduction in its capacity and compliance. After rectal surgery, smaller volumes of fecal material may be sufficient to induce contraction or spasm of the neorectum, which can cause symptoms such as urgency, soiling, or multiple evacuations. Although such symptoms may be obviated in part by the construction of a neorectal reservoir (eg, colonic J-pouch), the benefit lasts for fewer than 18 months [<a href="#rid16">16</a>], suggesting that reconstructive techniques play only a transient role in determining functional outcomes after sphincter-sparing surgery. (See  <a class="medical medical_review" href="/d/html/17127.html" rel="external">"Radical resection of rectal cancer", section on 'Anastomosis'</a>.)</p><p class="headingAnchor" id="H956453257"><span class="h2">Anal sphincter dysfunction</span><span class="headingEndMark"> — </span>Anal sphincter dysfunction can be a complication of rectal surgery or pelvic radiotherapy. In one study, up to 18 percent of patients who underwent stapled low anterior resection had evidence of long-term internal anal sphincter injury [<a href="#rid17">17</a>]. Intersphincteric resections performed to ensure an adequate distal margin can further alter sphincter functions. Anal sphincter dysfunction can contribute to LARS symptoms such as fecal incontinence or urgency.</p><p class="headingAnchor" id="H1122726640"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Since all patients who undergo a sphincter-sparing rectal resection are at risk of developing LARS, postoperative efforts should be made to prevent LARS. Upon hospital discharge, all patients should be instructed to perform home Kegel exercises as a form of pelvic floor muscle training. </p><p>Additionally, patients who receive a protective stoma as a part of their low anterior resection may be at increased risk of developing LARS. In a follow-up study 12 years after a randomized trial, patients who underwent low anterior resection with a protective stoma reported increased incontinence for flatus and liquid stools and worse overall LARS score compared with patients who underwent low anterior resection without a protective stoma [<a href="#rid18">18</a>]. Thus, patients who have a protective stoma that is not expected to close within one to two months should also receive daily or two- to three-times-per-week enemas or anterograde colonic irrigation via the stoma. (See <a class="local">'Colonic irrigation'</a> below.) </p><p class="headingAnchor" id="H2009857275"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Common symptoms of LARS include:</p><p class="bulletIndent1"><span class="glyph">●</span>Fecal urgency </p><p class="bulletIndent1"><span class="glyph">●</span>Fecal incontinence</p><p class="bulletIndent1"><span class="glyph">●</span>Increased frequency of bowel movements </p><p class="bulletIndent1"><span class="glyph">●</span>Fragmentation and clustering of bowel movements</p><p class="bulletIndent1"><span class="glyph">●</span>Emptying difficulties or incomplete evacuation</p><p class="bulletIndent1"><span class="glyph">●</span>Increased intestinal gas</p><p class="bulletIndent1"><span class="glyph">●</span>Diarrhea</p><p class="bulletIndent1"><span class="glyph">●</span>Constipation</p><p class="bulletIndent1"><span class="glyph">●</span>Change in stool consistency</p><p></p><p class="headingAnchor" id="H2571065779"><span class="h1">DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>LARS should be suspected in patients who develop one or more bowel symptoms after undergoing a sphincter-sparing resection of the rectum. The diagnosis is confirmed when the symptom(s) persist beyond one month after surgery and an evaluation fails to elucidate an alternative etiology. </p><p>Although bowel symptoms are common after rectal surgery, not all should be attributed to LARS. Patients with the following complaints require an evaluation to exclude alternative diagnoses: </p><p class="bulletIndent1"><span class="glyph">●</span>Patients who have sepsis or peritonitis may have an anastomotic failure. Abdominopelvic computed tomography (CT) or <a class="drug drug_general" data-topicid="9180" href="/d/drug information/9180.html" rel="external">barium</a> enema can be used to exclude anastomotic complications. (See  <a class="medical medical_review" href="/d/html/15687.html" rel="external">"Management of anastomotic complications of colorectal surgery"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who have bloody diarrhea may have inflammatory bowel disease, toxic colitis, ischemic colitis, or chemotherapy-induced colitis. Endoscopic examination of the lower gastrointestinal tract with colonoscopy, sigmoidoscopy, proctoscopy, or anoscopy could reveal mucosal alterations or enable tissue biopsy to confirm the diagnosis. (See  <a class="medical medical_review" href="/d/html/4067.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults"</a> and  <a class="medical medical_review" href="/d/html/4070.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of Crohn disease in adults"</a> and  <a class="medical medical_review" href="/d/html/1381.html" rel="external">"Toxic megacolon"</a> and  <a class="medical medical_review" href="/d/html/2564.html" rel="external">"Colonic ischemia"</a> and  <a class="medical medical_review" href="/d/html/2824.html" rel="external">"Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who have tissue prolapse from the rectum may have rectal/neorectal prolapse or other pelvic organ prolapse such as pelvic/perineal hernia or enterocele. <a class="drug drug_general" data-topicid="9180" href="/d/drug information/9180.html" rel="external">Barium</a> or magnetic resonance defecography can detect enteroceles, rectoceles, or rectal prolapse in addition to evaluating the length of the anal sphincter, anorectal angle, and pelvic descent. (See  <a class="medical medical_review" href="/d/html/15025.html" rel="external">"Overview of rectal procidentia (rectal prolapse)", section on 'Clinical features'</a> and  <a class="medical medical_review" href="/d/html/15025.html" rel="external">"Overview of rectal procidentia (rectal prolapse)", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/d/html/15712.html" rel="external">"Management of perineal complications following an abdominal perineal resection", section on 'Perineal hernia'</a> and  <a class="medical medical_review" href="/d/html/8072.html" rel="external">"Pelvic organ prolapse in females: Epidemiology, risk factors, clinical manifestations, and management", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/d/html/2637.html" rel="external">"Etiology and evaluation of chronic constipation in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who have obstructive symptoms, such as nausea, vomiting, or obstipation, may have postoperative adhesions. Abdominopelvic CT is the imaging modality of choice to diagnose a bowel obstruction. (See  <a class="medical medical_review" href="/d/html/2891.html" rel="external">"Postoperative peritoneal adhesions in adults and their prevention", section on 'Clinical presentations and diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who have fecal incontinence should undergo endoscopic ultrasound examination of the anal sphincter complex to rule out a sphincter injury. Additionally, neurophysiologic tests (eg, electromyography [EMG]) can be performed in patients with clinically suspected neurogenic sphincter weakness, particularly if there are features suggestive of sacral root involvement. (See  <a class="medical medical_review" href="/d/html/2667.html" rel="external">"Endorectal endoscopic ultrasound (EUS) in the evaluation of fecal incontinence"</a> and  <a class="medical medical_review" href="/d/html/2561.html" rel="external">"Fecal incontinence in adults: Etiology and evaluation", section on 'Other'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients whose main symptoms are excessive gas, flatulence, or abdominal bloating may have small intestinal bacterial overgrowth (SIBO). SIBO can be diagnosed by a lactose breath test. (See  <a class="medical medical_review" href="/d/html/4780.html" rel="external">"Approach to the adult patient with suspected malabsorption", section on 'Small intestinal bacterial overgrowth'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients suspected of having recurrent rectal cancer based on postsurgical surveillance should undergo colonoscopy to confirm the diagnosis. (See  <a class="medical medical_review" href="/d/html/2493.html" rel="external">"Post-treatment surveillance after colorectal cancer treatment"</a> and  <a class="medical medical_review" href="/d/html/2528.html" rel="external">"Treatment of locally recurrent rectal adenocarcinoma", section on 'Mode of presentation'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients whose bowel symptoms predate sphincter-sparing surgery may have irritable bowel syndrome. However, LARS can be difficult to distinguish from diarrhea-predominant irritable bowel syndrome (IBS-D) because the symptoms overlap and both are diagnoses of exclusion. (See  <a class="medical medical_review" href="/d/html/2630.html" rel="external">"Clinical manifestations and diagnosis of irritable bowel syndrome in adults", section on 'Diarrhea'</a>.)</p><p></p><p class="headingAnchor" id="H1583723073"><span class="h1">DIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>Evaluation of LARS begins with a history and physical examination. Patient questionnaires, such as the Low Anterior Resection Syndrome Score or the Memorial Sloan Kettering Cancer Center Bowel Function Instrument, should be used to stratify patients based upon the severity of their symptoms and to guide therapy. Although they are not diagnostic, adjunctive tests, such as manometry, imaging, or endoscopy, may be required to elucidate etiology, exclude alternative diagnosis, or guide treatment. (See <a class="local">'Diagnosis and differential diagnosis'</a> above.)</p><p class="headingAnchor" id="H3439156381"><span class="h2">Patient questionnaires</span><span class="headingEndMark"> — </span>Two patient questionnaires have been validated and widely used for assessing patients with LARS. Scores generated by such instruments are not used to diagnose LARS but to quantify the severity of the illness and to monitor the effectiveness of therapy.</p><p class="bulletIndent1"><span class="glyph">●</span>The<strong> Low Anterior Resection Syndrome Score</strong> (LARS score; 2012) is a validated questionnaire for assessing bowel function after sphincter-sparing surgery for rectal cancer [<a href="#rid19">19</a>]. Only five questions are asked by this questionnaire: incontinence for flatus, incontinence for liquid stool, fecal frequency (number of bowel movements per day), clustering of (less than an hour between) bowel movements, and urgency (<a class="calc calc_professional" href="/d/html/109489.html" rel="external">calculator 1</a>). Based upon their scores, patients are stratified into minor or major LARS. Major LARS, defined by a LARS score of ≥30, is typically associated with seriously compromised quality of life and therefore requires intensive or invasive treatment. Minor LARS (score &lt;30) can be treated medically for individual symptoms. (See <a class="local">'Treatment'</a> below.)</p><p></p><p class="bulletIndent1">The LARS score is widely used in clinical practice owing to its conciseness and ease of scoring. Its severity categories are also clinically meaningful and correlate with patients' quality of life. The LARS score has been translated from Danish into many other languages (English, Dutch, Swedish, Spanish, Chinese, German, and Lithuanian) and has been validated in those respective countries. </p><p></p><p class="bulletIndent1">However, the LARS score may be insensitive to evacuatory dysfunction and overestimate the impact on quality of life for some patients [<a href="#rid20">20</a>]. There is also a high rate of LARS-like symptoms in the general population. As an example, a study in Denmark reported that 19 percent of females and 10 percent of males from the general population had a LARS score ≥30, corresponding to the category of "major LARS," and the median score for females and males surveilled was 16 (7 to 26) and 11 (4 to 22), respectively [<a href="#rid21">21</a>]. This reflects the high sensitivity but low specificity of the LARS score. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The<strong> Memorial Sloan Kettering Cancer Center Bowel Function Instrument</strong> (MSKCC BFI; 2005) was the first questionnaire specifically validated for evaluating bowel function after sphincter-sparing surgery for rectal cancer [<a href="#rid22">22</a>]. It consists of 18 questions on a variety of LARS-related issues. Its complexity in scoring (which involves recoding, three subscale scores, a global score, and a total score) limits its use in clinical practice. </p><p></p><p class="headingAnchor" id="H3562653893"><span class="h2">Anorectal/colonic manometry</span><span class="headingEndMark"> — </span>Anorectal/colonic manometry is not required to diagnose LARS but can be helpful in monitoring patient response to treatment, especially for major LARS. (See <a class="local">'Neurostimulation'</a> below.)</p><p>Resting and squeeze sphincter pressures in LARS are typically normal or reduced. In some patients, however, the sphincter pressure may be increased as an involuntary response to fecal incontinence or abnormal straining maneuvers in a dyssynergic pattern. </p><p>In LARS, both the capacity and compliance of the neorectum are typically reduced compared with the presurgical baseline. The neorectal sensibility can be normal, reduced, or increased depending upon the anastomotic height, any inflammation or anastomotic complication in the neorectum, or previous pelvic radiotherapy. </p><p>Colonic manometry in LARS often reveals a reduction in segmental contractile activities and an increase in high-amplitude propagated contractions. The latter is correlated with colonic mass movements.</p><p class="headingAnchor" id="H2031757806"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>At one month after the initial surgery without a stoma or after the protective stoma is closed, patients who have persistent bowel symptoms are diagnosed with LARS and evaluated with one of the patient questionnaires, such as the LARS score. Further treatment options are dependent upon the LARS score.</p><p>LARS can be treated with medications, transanal irrigation, pelvic floor rehabilitation, neurostimulation, or surgery [<a href="#rid23">23</a>]. The choice of treatment(s) is based upon the variety, severity, and duration of symptoms  (<a class="graphic graphic_algorithm graphicRef110090" href="/d/graphic/110090.html" rel="external">algorithm 1</a>).</p><p>For most patients with LARS, nonoperative therapies, including pelvic floor rehabilitation and transanal irrigation, and minimally invasive procedures such as sacral nerve stimulation are the mainstay of treatment. A multimodal approach generally works better than any single therapy. Given the lack of high-quality evidence in this field, recommendations are generally based upon retrospective studies or extrapolated from studies on nonsurgical patients with similar gastrointestinal disorders (eg, irritable bowel syndrome) [<a href="#rid24">24</a>].</p><p>Counselling and follow-up of patients with LARS should be organized proactively and include a clinical nurse specialist [<a href="#rid25">25</a>]. </p><p class="headingAnchor" id="H2212458905"><span class="h2">Minor LARS</span><span class="headingEndMark"> — </span>Patients who have a LARS score &lt;30 have minor LARS. Patients with minor LARS typically have preserved quality of life, and most can be treated medically for one or more specific symptom(s), including  (<a class="graphic graphic_algorithm graphicRef110090" href="/d/graphic/110090.html" rel="external">algorithm 1</a>): </p><p class="headingAnchor" id="H1334179129"><span class="h3">Diarrhea</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9571" href="/d/drug information/9571.html" rel="external">Loperamide</a> is most commonly used to treat diarrhea associated with LARS. Although loperamide has not been specifically studied in LARS, its use is supported by its efficacy in treating two similar disorders, diarrhea-predominant irritable bowel syndrome (IBS-D) and bowel dysfunction after restorative proctocolectomy (see  <a class="medical medical_review" href="/d/html/2631.html" rel="external">"Treatment of irritable bowel syndrome in adults"</a> and  <a class="medical medical_review" href="/d/html/15017.html" rel="external">"Restorative proctocolectomy with ileal pouch-anal anastomosis: Laparoscopic approach", section on 'Functional results'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9571" href="/d/drug information/9571.html" rel="external">Loperamide</a> is the only antidiarrheal agent that has been evaluated in randomized trials in patients with IBS-D [<a href="#rid26">26</a>]. In IBS-D patients, loperamide was more effective than placebo in reducing the number of bowel movements and improving stool consistency. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients who have undergone a restorative proctocolectomy with construction of an ileoanal pouch, <a class="drug drug_general" data-topicid="9571" href="/d/drug information/9571.html" rel="external">loperamide</a> significantly lowered stool frequency and modified some aspects of pouch contraction in one study [<a href="#rid27">27</a>] and improved anal sphincter function and continence in another [<a href="#rid28">28</a>]. </p><p></p><p>In patients with persistent diarrhea despite antidiarrheals, bile acid sequestrants can be used. Bile acid malabsorption can occur after colorectal surgery and cause symptoms such as diarrhea, fecal urgency, frequency, or incontinence. Having been successfully used to treat bile acid malabsorption after pelvic radiation [<a href="#rid29">29</a>] and from IBS-D [<a href="#rid30">30</a>], bile acid sequestrants (eg, <a class="drug drug_general" data-topicid="8954" href="/d/drug information/8954.html" rel="external">colesevelam</a>) are being investigated as potential treatments for LARS. (See  <a class="medical medical_review" href="/d/html/2631.html" rel="external">"Treatment of irritable bowel syndrome in adults", section on 'Bile acid sequestrants'</a>.)</p><p class="headingAnchor" id="H4036757992"><span class="h3">Postprandial urgency or incontinence</span><span class="headingEndMark"> — </span>Some patients with LARS have an exaggerated postprandial response in the neorectum of urgency and/or incontinence. For such patients, one of the serotonin- (5-hydroxytryptamine)-3 receptor (5-HT<sub>3</sub>) antagonists, in particular ramosetron, may be used to control their symptoms.</p><p>In one trial, 100 male patients with LARS one month after rectal cancer surgery or ileostomy reversal were treated with 5 mcg of ramosetron hydrochloride daily or routine management [<a href="#rid31">31</a>]. After one month, fewer patients who received ramosetron (58 versus 82 percent) still had major LARS. There were no major adverse effects or difference in minor adverse effects. </p><p>Other 5-HT<sub>3</sub> antagonists (eg, <a class="drug drug_general" data-topicid="9299" href="/d/drug information/9299.html" rel="external">alosetron</a> or cilansetron) have also been used to treat exaggerated intestinal/colonic hypermotility in IBS-D patients but have not been studied in LARS patients. (See  <a class="medical medical_review" href="/d/html/2631.html" rel="external">"Treatment of irritable bowel syndrome in adults", section on '5-hydroxytryptamine (serotonin) 3 receptor antagonists'</a>.)</p><p class="headingAnchor" id="H240300524"><span class="h3">Gas and bloating</span><span class="headingEndMark"> — </span>Patients whose main symptoms are excessive gas, flatulence, or abdominal bloating can be treated with antibiotics such as <a class="drug drug_general" data-topicid="10202" href="/d/drug information/10202.html" rel="external">rifaximin</a> or <a class="drug drug_general" data-topicid="9686" href="/d/drug information/9686.html" rel="external">neomycin</a>. Symptoms related to excessive intestinal gas production, including flatulence and abdominal bloating, can be caused by small intestinal bacterial overgrowth (SIBO). SIBO occurs with expansion of gut microbes from the colon to the small intestine, where the microbes produce excessive intestinal gas by abnormal fermentation of food [<a href="#rid32">32</a>]. Antibiotics, such as neomycin and rifaximin, can help reduce or eliminate SIBO. (See  <a class="medical medical_review" href="/d/html/4778.html" rel="external">"Small intestinal bacterial overgrowth: Management"</a>.)</p><p class="headingAnchor" id="H1689258512"><span class="h3">Fecal soilage</span><span class="headingEndMark"> — </span>In patients whose main symptoms are soiling or mild passive fecal incontinence, intra-anal injection of bulking agents can be used as part of a multimodal approach. Its value as a stand-alone therapy, however, is limited. (See  <a class="medical medical_review" href="/d/html/96913.html" rel="external">"Fecal incontinence in adults: Management", section on 'Injectable anal bulking agents'</a>.)</p><p class="headingAnchor" id="H3448480846"><span class="h3">Ineffective medical treatments</span><span class="headingEndMark"> — </span>First-line conservative measures, such as dietary restrictions, fiber, constipating agents, or enemas, typically do not have good control of LARS symptoms; their impact on patient satisfaction and quality of life is doubtful and not supported by evidence. The following medications or supplements have been tried and found ineffective against LARS symptoms:</p><p class="bulletIndent1"><span class="glyph">●</span>Probiotics have a limited role in the prevention or treatment of LARS. In one study, the use of a probiotic preparation, VSL#3, did not alter the postoperative bowel function of patients undergoing loop ileostomy reversal after a sphincter-sparing resection [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fiber intake can improve stool consistency by absorbing water but not any other bowel symptoms. It is often poorly tolerated in LARS patients due to bloating and abdominal pain.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is no evidence supporting the use of steroids or nonsteroidal anti-inflammatory drugs in the treatment of LARS.</p><p></p><p class="headingAnchor" id="H1487209709"><span class="h2">Major LARS</span><span class="headingEndMark"> — </span>Patients who have a LARS score ≥30 have major LARS. Major LARS has a significant negative impact on patients' quality of life. Thus, patients with major LARS typically require multimodal therapy rather than medical treatment for individual symptoms as described above  (<a class="graphic graphic_algorithm graphicRef110090" href="/d/graphic/110090.html" rel="external">algorithm 1</a>).</p><p>Multimodal therapy for LARS consists of transanal irrigation (TAI) daily or three to four times per week plus pelvic floor rehabilitation (including biofeedback, pelvic floor muscle training, balloon training, and electrostimulation). Patients who have major LARS should receive such treatment for six months to one year before they are reevaluated with the LARS score. Patients who no longer have major LARS on repeat evaluation can be treated medically for any symptoms that persist. (See <a class="local">'Minor LARS'</a> above.)</p><p>Patients who continue to have major LARS after one year of multimodal therapy should be treated with neurostimulation (eg, sacral nerve stimulation). Patients who do not respond to neurostimulation and continue to have major LARS and severely compromised quality of life should be offered a diverting stoma in another year (ie, after a total of two years from the start of multimodal therapy).</p><p class="headingAnchor" id="H280615174"><span class="h3">Colonic irrigation</span><span class="headingEndMark"> — </span>TAI is a simple, safe, effective, and inexpensive treatment for LARS patients who primarily have symptoms of fecal incontinence or frequency [<a href="#rid34">34,35</a>]. TAI is typically used in conjunction with pelvic floor rehabilitation in those with major LARS. (See  <a class="medical medical_review" href="/d/html/1384.html" rel="external">"Ileostomy or colostomy care and complications", section on 'Colon irrigation'</a>.)</p><p>Low-volume TAI simply achieves the effect of a mechanical washout. High-volume (&gt;250 mL) irrigation generates functional colonic responses, such as colonic mass movements, which improves colonic transit time and fecal continence when administered regularly. Patients who have low rectal volume, low maximal rectal capacity, and/or low anal squeeze pressure respond most favorably to TAI. </p><p>TAI for LARS is typically performed transanally in a retrograde fashion. Patients are trained by a stoma nurse to perform TAI with one of the commercially available systems (eg, the Peristeen anal irrigation system) daily or three to four times per week. During each treatment, 500 to 1500 mL of water was instilled into the colon [<a href="#rid34">34</a>]. </p><p>In a trial of 45 patients with major LARS following rectal cancer surgery and total mesorectal excision, TAI resulted in lower LARS score (23 versus 32) and improved quality of life compared with conservative management at one year [<a href="#rid36">36</a>]. </p><p>In one study of 14 patients with LARS, the number of bowel movements during the day and at night both decreased (8 to 1 and 3 to 0, respectively), and quality of life improved after regular TAI for an average of 29 months [<a href="#rid34">34</a>]. In another study of 33 patients, the median LARS score fell from 35.1 (range 30 to 42) to 12.2 (range 0 to 21) after six months of TAI, and quality of life improved in several domains as well [<a href="#rid37">37</a>]. </p><p>The risk of bowel perforation associated with TAI has been estimated to be about 2 per million procedures [<a href="#rid38">38</a>]. Risk factors include suboptimal patient evaluation, wrong indications, lack of training, and poor patient compliance. </p><p>One center in France treated 25 patients for major LARS after total mesorectal excision with anterograde enema (one liter of tap water) administered via a percutaneous endoscopic cecostomy (PEC) [<a href="#rid39">39</a>]. LARS score significantly improved after treatment (33 versus 4). At the end of the follow-up (median 8 months, range 1 to 33 months), the PEC catheter was removed from four patients (16 percent), indicating treatment failure; three of the four patients underwent a permanent colostomy.</p><p class="headingAnchor" id="H3587941507"><span class="h3">Pelvic floor rehabilitation</span><span class="headingEndMark"> — </span>LARS patients who present with fecal incontinence or frequency can also benefit from pelvic floor rehabilitation (PFR). PFR is typically used in conjunction with TAI in those with major LARS.</p><p>PFR refers to a collection of rehabilitative techniques that includes biofeedback, pelvic floor muscle training, electrostimulation, and volumetric/rectal balloon training. Specific techniques are selected according to the individual needs of each patient, although a combination of techniques has been shown to significantly improve outcomes compared with individual techniques alone [<a href="#rid40">40</a>]. </p><p>Both pelvic floor muscle training [<a href="#rid41">41-43</a>] and biofeedback [<a href="#rid44">44</a>] have been associated with improvements in bowel function and health-related quality of life in patients with LARS: </p><p class="bulletIndent1"><span class="glyph">●</span>In one small trial of about 100 patients, those who performed pelvic floor muscle training regularly starting at one month after sphincter-sparing resection or ostomy closure reported greater improvement in LARS category than controls at four and six months, but not 12 months [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study of patients after sphincter-sparing surgery, significant improvements were observed after biofeedback therapy in fecal incontinence score, number of bowel movements, and anorectal manometry data (maximum resting pressure, maximum squeeze pressure, and rectal capacity) [<a href="#rid44">44</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a third study, patients with LARS benefited equally from PFR regardless of whether they received adjuvant pelvic radiotherapy [<a href="#rid46">46</a>]. </p><p></p><p>However, the available studies on PFR in LARS are generally of low quality due to the heterogeneity in the PFR protocols and fecal incontinence scoring systems used. A 2015 systematic review concluded that the majority of studies reported significant improvements in stool frequency, incontinence episodes, severity of fecal incontinence, and quality of life after pelvic floor muscle training, but a meta-analysis was not possible due to the heterogeneity in study designs. High-quality data are required to validate the efficacy of PFR used for LARS.</p><p>The same PFR techniques are used to treat patients with pelvic organ prolapse, urinary incontinence, or pelvic pain syndrome and are further discussed in other topics. (See  <a class="medical medical_review" href="/d/html/5491.html" rel="external">"Myofascial pelvic pain syndrome in females: Pelvic floor physical therapy for management"</a> and  <a class="medical medical_review" href="/d/html/8072.html" rel="external">"Pelvic organ prolapse in females: Epidemiology, risk factors, clinical manifestations, and management", section on 'Pelvic floor muscle exercises'</a> and  <a class="medical medical_review" href="/d/html/6881.html" rel="external">"Female urinary incontinence: Treatment", section on 'Pelvic floor muscle (Kegel) exercises'</a>.)</p><p class="headingAnchor" id="H3635968101"><span class="h3">Neurostimulation</span><span class="headingEndMark"> — </span>Patients who continue to have major LARS after one year of multimodal therapy should be evaluated for neurostimulation (eg, sacral nerve stimulation [SNS]). SNS has been shown to improve fecal incontinence and the ability to defer defecation in patients with normal or impaired sphincters [<a href="#rid47">47</a>]. </p><p>SNS was initially thought to directly act upon anal sphincter muscles through peripheral motor stimulation to increase resting and squeeze pressures but is now believed to exert more influence on anorectal functions at a pelvic afferent or central level. Additionally, SNS has also been shown to decrease anterograde while increasing retrograde colonic motor activities [<a href="#rid48">48</a>] and to impair postprandial changes in rectal motility [<a href="#rid49">49</a>]. The latter two mechanisms are most relevant for LARS patients. </p><p>SNS involves placement of an electrode into the sacral foramen to provide low-grade electrical stimulation to the sacral nerve. Patients who respond to a two-week trial with a temporary electrode then undergo placement of a permanent electrode connected to a generator embedded subcutaneously.</p><p>SNS has been studied in patients with LARS [<a href="#rid50">50-57</a>]; approximately 72 percent of patients who underwent temporary stimulation went on to receive a permanent stimulator  (<a class="graphic graphic_table graphicRef109246" href="/d/graphic/109246.html" rel="external">table 1</a>). After a follow-up of 12 to 32 months, most patients achieved good functional results with improvements in incontinence episodes, the ability to defer bowel movement, fragmentation or urgency in defecation, and quality of life. Manometric results varied and did not always correlate with functional outcomes. </p><p>Similar conclusions were reached by a 2015 systematic review, which included 43 patients with a median follow-up of 15 months [<a href="#rid58">58</a>]. In that study, 79 percent of patients who underwent temporary stimulation received a permanent stimulator, 94 percent of whom experienced improvement of symptoms. However, all the studies that have been conducted to date are small, retrospective, and heterogenous; high-quality evidence is required to validate SNS as a standard treatment for LARS.</p><p>Other techniques of neurostimulation (eg, posterior tibial nerve stimulation [PTNS] and electroacupuncture) are being investigated as potential treatments for LARS but are not yet available for widespread clinical use. In a trial of 46 patients with LARS, LARS scores were reduced from 36.4 (standard deviation 3.9) to 30.7 (11.5) at 12 months, and fecal incontinence scores were reduced from 15.4 (5.2) to 12.5 (6.4) after PTNS [<a href="#rid59">59</a>]. The LARS scores were also reduced in the sham control group, but the effect was not sustained. </p><p class="headingAnchor" id="H1023135334"><span class="h3">Surgery</span><span class="headingEndMark"> — </span>Patients with intractable LARS despite all other treatments may require surgery. Surgical options include anal sphincter substitution and fecal diversion. </p><p>Anal sphincter substitution by electrostimulated graciloplasty or an artificial sphincter has been performed to treat intractable fecal incontinence, but not in LARS patients. The procedure is associated with a high complication rate and significant costs.</p><p>Fecal diversion by stoma is the option of last resort after all other treatment modalities have failed. It is only elected if the patient has low quality of life due to symptoms from major LARS after two years of conservative or minimally invasive (eg, SNS) treatment. (See  <a class="medical medical_review" href="/d/html/15026.html" rel="external">"Overview of surgical ostomy for fecal diversion"</a>.)</p><p class="headingAnchor" id="H2263013643"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>LARS can continue to affect patients long after the surgery has concluded. In a study of 242 patients who were followed for a median of 14.6 years after sphincter-sparing resection, major LARS was reported by 46 percent [<a href="#rid3">3</a>]. Active prevention, prompt diagnosis, and multimodal treatment of LARS will have a significant benefit to these patients' quality of life.</p><p class="headingAnchor" id="H3235879783"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and epidemiology of low anterior resection syndrome</strong> – Low anterior resection syndrome (LARS) is a constellation of symptoms, such as fecal incontinence or urgency, frequent or fragmented bowel movements, emptying difficulties, and increased intestinal gas, that occur after a sphincter-sparing resection (ie, anterior resection) of the rectum. An estimated 25 to 80 percent of patients develop LARS following a sphincter-sparing rectal surgery, and symptoms persist beyond 10 years in 50 percent of patients. (See <a class="local">'Definition'</a> above and <a class="local">'Epidemiology and risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention of LARS</strong> – After a sphincter-sparing rectal resection, we suggest pelvic floor muscle training with home Kegel exercises for all patients (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Additionally, those who have a protective stoma that is not expected to close within one to two months should also receive daily or two- to three-times-per-week enemas or anterograde colonic irrigation via the stoma. (See <a class="local">'Prevention'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis of LARS</strong> – LARS should be suspected in patients who develop one or more bowel symptoms after undergoing a sphincter-sparing resection of the rectum. The diagnosis is confirmed after the symptom(s) persist for one month after surgery and an evaluation fails to elucidate an alternative etiology. (See <a class="local">'Diagnosis and differential diagnosis'</a> above and <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation</strong> – At one month after the initial surgery or after the protective stoma is closed, patients who have persistent bowel symptoms should be formally evaluated with one of the patient questionnaires, such as the LARS score. Further treatment options are dependent upon the LARS score. Although anorectal/colonic manometry is not required to diagnose LARS, it can be helpful in monitoring patient response to treatment, especially for major LARS, when available  (<a class="graphic graphic_algorithm graphicRef110090" href="/d/graphic/110090.html" rel="external">algorithm 1</a>). (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medical treatment of minor LARS</strong> – For patients with minor LARS (LARS score &lt;30), we suggest medical treatment rather than more intensive or invasive modalities of therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Medical treatments for minor LARS should be individualized for each patient based on symptoms:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diarrhea – <a class="drug drug_general" data-topicid="9571" href="/d/drug information/9571.html" rel="external">Loperamide</a> (first-line) or <a class="drug drug_general" data-topicid="8954" href="/d/drug information/8954.html" rel="external">colesevelam</a> (second-line) (see <a class="local">'Diarrhea'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Postprandial urgency or incontinence – One of the serotonin- (5-hydroxytryptamine)-3 receptor (5-HT<sub>3</sub>) antagonists (eg, ramosetron) (see <a class="local">'Postprandial urgency or incontinence'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gas and bloating – Antibiotics (eg, <a class="drug drug_general" data-topicid="10202" href="/d/drug information/10202.html" rel="external">rifaximin</a> or <a class="drug drug_general" data-topicid="9686" href="/d/drug information/9686.html" rel="external">neomycin</a>) (see <a class="local">'Gas and bloating'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fecal soilage – Intra-anal injection of bulking agents (see <a class="local">'Fecal soilage'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of major LARS</strong> – For patients with major LARS (LARS score ≥30), we suggest intensive multimodal therapy including transanal irrigation and pelvic floor rehabilitation (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Colonic irrigation'</a> above and <a class="local">'Pelvic floor rehabilitation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>At one year, patients who continue to have major LARS should be offered a trial of sacral nerve stimulation (SNS) in addition to continued transanal irrigation and pelvic floor rehabilitation. (See <a class="local">'Neurostimulation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>At two years, or one year after sacral nerve stimulation has been attempted, patients who continue to have major LARS associated with a low quality of life should be offered fecal diversion by stoma. (See <a class="local">'Surgery'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Keane C, Fearnhead NS, Bordeianou LG, et al. International Consensus Definition of Low Anterior Resection Syndrome. Dis Colon Rectum 2020; 63:274.</a></li><li><a class="nounderline abstract_t">Sun R, Dai Z, Zhang Y, et al. The incidence and risk factors of low anterior resection syndrome (LARS) after sphincter-preserving surgery of rectal cancer: a systematic review and meta-analysis. Support Care Cancer 2021; 29:7249.</a></li><li><a class="nounderline abstract_t">Chen TY, Wiltink LM, Nout RA, et al. Bowel function 14 years after preoperative short-course radiotherapy and total mesorectal excision for rectal cancer: report of a multicenter randomized trial. Clin Colorectal Cancer 2015; 14:106.</a></li><li><a class="nounderline abstract_t">Sturiale A, Martellucci J, Zurli L, et al. Long-term functional follow-up after anterior rectal resection for cancer. Int J Colorectal Dis 2017; 32:83.</a></li><li><a class="nounderline abstract_t">Ihnát P, Slívová I, Tulinsky L, et al. Anorectal dysfunction after laparoscopic low anterior rectal resection for rectal cancer with and without radiotherapy (manometry study). J Surg Oncol 2018; 117:710.</a></li><li><a class="nounderline abstract_t">Downing A, Glaser AW, Finan PJ, et al. Functional Outcomes and Health-Related Quality of Life After Curative Treatment for Rectal Cancer: A Population-Level Study in England. Int J Radiat Oncol Biol Phys 2019; 103:1132.</a></li><li><a class="nounderline abstract_t">Quezada-Diaz F, Jimenez-Rodriguez RM, Pappou EP, et al. Effect of Neoadjuvant Systemic Chemotherapy With or Without Chemoradiation on Bowel Function in Rectal Cancer Patients Treated With Total Mesorectal Excision. J Gastrointest Surg 2019; 23:800.</a></li><li><a class="nounderline abstract_t">Keane CR, O'Grady G, Bissett IP, et al. Functional Outcome of Laparoscopic-Assisted Resection Versus Open Resection of Rectal Cancer: A Secondary Analysis of the Australasian Laparoscopic Cancer of the Rectum Trial. Dis Colon Rectum 2022; 65:e698.</a></li><li><a class="nounderline abstract_t">Martellucci J, Balestri R, Brusciano L, et al. Ileostomy versus colostomy: impact on functional outcomes after total mesorectal excision for rectal cancer. Colorectal Dis 2023; 25:1686.</a></li><li><a class="nounderline abstract_t">Koda K, Saito N, Seike K, et al. Denervation of the neorectum as a potential cause of defecatory disorder following low anterior resection for rectal cancer. Dis Colon Rectum 2005; 48:210.</a></li><li><a class="nounderline abstract_t">Lee WY, Takahashi T, Pappas T, et al. Surgical autonomic denervation results in altered colonic motility: an explanation for low anterior resection syndrome? Surgery 2008; 143:778.</a></li><li><a class="nounderline abstract_t">Kimura H, Shimada H, Ike H, et al. Colonic J-pouch decreases bowel frequency by improving the evacuation ratio. Hepatogastroenterology 2006; 53:854.</a></li><li><a class="nounderline abstract_t">Ng KS, Russo R, Gladman MA. Colonic transit in patients after anterior resection: prospective, comparative study using single-photon emission CT/CT scintigraphy. Br J Surg 2020; 107:567.</a></li><li><a class="nounderline abstract_t">Emmertsen KJ, Bregendahl S, Fassov J, et al. A hyperactive postprandial response in the neorectum--the clue to low anterior resection syndrome after total mesorectal excision surgery? Colorectal Dis 2013; 15:e599.</a></li><li><a class="nounderline abstract_t">Bregendahl S, Emmertsen KJ, Fassov J, et al. Neorectal hyposensitivity after neoadjuvant therapy for rectal cancer. Radiother Oncol 2013; 108:331.</a></li><li><a class="nounderline abstract_t">Brown CJ, Fenech DS, McLeod RS. Reconstructive techniques after rectal resection for rectal cancer. Cochrane Database Syst Rev 2008; :CD006040.</a></li><li><a class="nounderline abstract_t">Farouk R, Duthie GS, Lee PW, Monson JR. Endosonographic evidence of injury to the internal anal sphincter after low anterior resection: long-term follow-up. Dis Colon Rectum 1998; 41:888.</a></li><li><a class="nounderline abstract_t">Gadan S, Floodeen H, Lindgren R, Matthiessen P. Does a Defunctioning Stoma Impair Anorectal Function After Low Anterior Resection of the Rectum for Cancer? A 12-Year Follow-up of a Randomized Multicenter Trial. Dis Colon Rectum 2017; 60:800.</a></li><li><a class="nounderline abstract_t">Emmertsen KJ, Laurberg S. Low anterior resection syndrome score: development and validation of a symptom-based scoring system for bowel dysfunction after low anterior resection for rectal cancer. Ann Surg 2012; 255:922.</a></li><li><a class="nounderline abstract_t">Ribas Y, Aguilar F, Jovell-Fernández E, et al. Clinical application of the LARS score: results from a pilot study. Int J Colorectal Dis 2017; 32:409.</a></li><li><a class="nounderline abstract_t">Juul T, Elfeki H, Christensen P, et al. Normative Data for the Low Anterior Resection Syndrome Score (LARS Score). Ann Surg 2019; 269:1124.</a></li><li><a class="nounderline abstract_t">Temple LK, Bacik J, Savatta SG, et al. The development of a validated instrument to evaluate bowel function after sphincter-preserving surgery for rectal cancer. Dis Colon Rectum 2005; 48:1353.</a></li><li><a class="nounderline abstract_t">Emile SH, Garoufalia Z, Barsom S, et al. Systematic review and meta-analysis of randomized clinical trials on the treatment of low anterior resection syndrome. Surgery 2023; 173:1352.</a></li><li><a class="nounderline abstract_t">Christensen P, Im Baeten C, Espín-Basany E, et al. Management guidelines for low anterior resection syndrome - the MANUEL project. Colorectal Dis 2021; 23:461.</a></li><li><a class="nounderline abstract_t">Pape E, Van Haver D, Lievrouw A, et al. Interprofessional perspectives on care for patients with low anterior resection syndrome: A qualitative study. Colorectal Dis 2022; 24:1032.</a></li><li><a class="nounderline abstract_t">Lazaraki G, Chatzimavroudis G, Katsinelos P. Recent advances in pharmacological treatment of irritable bowel syndrome. World J Gastroenterol 2014; 20:8867.</a></li><li><a class="nounderline abstract_t">Cohen LD, Levitt MD. A comparison of the effect of loperamide in oral or suppository form vs placebo in patients with ileo-anal pouches. Colorectal Dis 2001; 3:95.</a></li><li><a class="nounderline abstract_t">Hallgren T, Fasth S, Delbro DS, et al. Loperamide improves anal sphincter function and continence after restorative proctocolectomy. Dig Dis Sci 1994; 39:2612.</a></li><li><a class="nounderline abstract_t">Wedlake L, Thomas K, Lalji A, et al. Effectiveness and tolerability of colesevelam hydrochloride for bile-acid malabsorption in patients with cancer: a retrospective chart review and patient questionnaire. Clin Ther 2009; 31:2549.</a></li><li><a class="nounderline abstract_t">Odunsi-Shiyanbade ST, Camilleri M, McKinzie S, et al. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol 2010; 8:159.</a></li><li><a class="nounderline abstract_t">Ryoo SB, Park JW, Lee DW, et al. Anterior resection syndrome: a randomized clinical trial of a 5-HT3 receptor antagonist (ramosetron) in male patients with rectal cancer. Br J Surg 2021; 108:644.</a></li><li><a class="nounderline abstract_t">Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 2004; 292:852.</a></li><li><a class="nounderline abstract_t">Stephens JH, Hewett PJ. Clinical trial assessing VSL#3 for the treatment of anterior resection syndrome. ANZ J Surg 2012; 82:420.</a></li><li><a class="nounderline abstract_t">Rosen H, Robert-Yap J, Tentschert G, et al. Transanal irrigation improves quality of life in patients with low anterior resection syndrome. Colorectal Dis 2011; 13:e335.</a></li><li><a class="nounderline abstract_t">Falletto E, Martellucci J, Rossitti P, et al. Transanal irrigation in functional bowel disorders and LARS: short-term results from an Italian national study. Tech Coloproctol 2023; 27:481.</a></li><li><a class="nounderline abstract_t">Pieniowski EHA, Bergström CM, Nordenvall CAM, et al. A Randomized Controlled Clinical Trial of Transanal Irrigation Versus Conservative Treatment in Patients With Low Anterior Resection Syndrome After Rectal Cancer Surgery. Ann Surg 2023; 277:30.</a></li><li><a class="nounderline abstract_t">Martellucci J, Sturiale A, Bergamini C, et al. Role of transanal irrigation in the treatment of anterior resection syndrome. Tech Coloproctol 2018; 22:519.</a></li><li><a class="nounderline abstract_t">Christensen P, Krogh K, Perrouin-Verbe B, et al. Global audit on bowel perforations related to transanal irrigation. Tech Coloproctol 2016; 20:109.</a></li><li><a class="nounderline abstract_t">Didailler R, Denost Q, Loughlin P, et al. Antegrade Enema After Total Mesorectal Excision for Rectal Cancer: The Last Chance to Avoid Definitive Colostomy for Refractory Low Anterior Resection Syndrome and Fecal Incontinence. Dis Colon Rectum 2018; 61:667.</a></li><li><a class="nounderline abstract_t">Pucciani F, Ringressi MN, Redditi S, et al. Rehabilitation of fecal incontinence after sphincter-saving surgery for rectal cancer: encouraging results. Dis Colon Rectum 2008; 51:1552.</a></li><li><a class="nounderline abstract_t">Lin KY, Granger CL, Denehy L, Frawley HC. Pelvic floor muscle training for bowel dysfunction following colorectal cancer surgery: A systematic review. Neurourol Urodyn 2015; 34:703.</a></li><li><a class="nounderline abstract_t">Liu CH, Chen CH, Lee JC. Rehabilitation exercise on the quality of life in anal sphincter-preserving surgery. Hepatogastroenterology 2011; 58:1461.</a></li><li><a class="nounderline abstract_t">Laforest A, Bretagnol F, Mouazan AS, et al. Functional disorders after rectal cancer resection: does a rehabilitation programme improve anal continence and quality of life? Colorectal Dis 2012; 14:1231.</a></li><li><a class="nounderline abstract_t">Kim KH, Yu CS, Yoon YS, et al. Effectiveness of biofeedback therapy in the treatment of anterior resection syndrome after rectal cancer surgery. Dis Colon Rectum 2011; 54:1107.</a></li><li><a class="nounderline abstract_t">Asnong A, D'Hoore A, Van Kampen M, et al. The Role of Pelvic Floor Muscle Training on Low Anterior Resection Syndrome: A Multicenter Randomized Controlled Trial. Ann Surg 2022; 276:761.</a></li><li><a class="nounderline abstract_t">Allgayer H, Dietrich CF, Rohde W, et al. Prospective comparison of short- and long-term effects of pelvic floor exercise/biofeedback training in patients with fecal incontinence after surgery plus irradiation versus surgery alone for colorectal cancer: clinical, functional and endoscopic/endosonographic findings. Scand J Gastroenterol 2005; 40:1168.</a></li><li><a class="nounderline abstract_t">Thin NN, Horrocks EJ, Hotouras A, et al. Systematic review of the clinical effectiveness of neuromodulation in the treatment of faecal incontinence. Br J Surg 2013; 100:1430.</a></li><li><a class="nounderline abstract_t">Michelsen HB, Christensen P, Krogh K, et al. Sacral nerve stimulation for faecal incontinence alters colorectal transport. Br J Surg 2008; 95:779.</a></li><li><a class="nounderline abstract_t">Michelsen HB, Worsøe J, Krogh K, et al. Rectal motility after sacral nerve stimulation for faecal incontinence. Neurogastroenterol Motil 2010; 22:36.</a></li><li><a class="nounderline abstract_t">Matzel KE, Stadelmaier U, Bittorf B, et al. Bilateral sacral spinal nerve stimulation for fecal incontinence after low anterior rectum resection. Int J Colorectal Dis 2002; 17:430.</a></li><li><a class="nounderline abstract_t">Ratto C, Grillo E, Parello A, et al. Sacral neuromodulation in treatment of fecal incontinence following anterior resection and chemoradiation for rectal cancer. Dis Colon Rectum 2005; 48:1027.</a></li><li><a class="nounderline abstract_t">Jarrett ME, Matzel KE, Stösser M, et al. Sacral nerve stimulation for faecal incontinence following a rectosigmoid resection for colorectal cancer. Int J Colorectal Dis 2005; 20:446.</a></li><li><a class="nounderline abstract_t">Melenhorst J, Koch SM, Uludag O, et al. Sacral neuromodulation in patients with faecal incontinence: results of the first 100 permanent implantations. Colorectal Dis 2007; 9:725.</a></li><li><a class="nounderline abstract_t">Holzer B, Rosen HR, Zaglmaier W, et al. Sacral nerve stimulation in patients after rectal resection--preliminary report. J Gastrointest Surg 2008; 12:921.</a></li><li><a class="nounderline abstract_t">de Miguel M, Oteiza F, Ciga MA, et al. Sacral nerve stimulation for the treatment of faecal incontinence following low anterior resection for rectal cancer. Colorectal Dis 2011; 13:72.</a></li><li><a class="nounderline abstract_t">Moya P, Arroyo A, Soriano-Irigaray L, et al. Sacral nerve stimulation in patients with severe fecal incontinence after rectal resection. Tech Coloproctol 2012; 16:263.</a></li><li><a class="nounderline abstract_t">Schwandner O. Sacral neuromodulation for fecal incontinence and "low anterior resection syndrome" following neoadjuvant therapy for rectal cancer. Int J Colorectal Dis 2013; 28:665.</a></li><li><a class="nounderline abstract_t">Ramage L, Qiu S, Kontovounisios C, et al. A systematic review of sacral nerve stimulation for low anterior resection syndrome. Colorectal Dis 2015; 17:762.</a></li><li><a class="nounderline abstract_t">Marinello FG, Jiménez LM, Talavera E, et al. Percutaneous tibial nerve stimulation in patients with severe low anterior resection syndrome: randomized clinical trial. Br J Surg 2021; 108:380.</a></li></ol></div><div id="topicVersionRevision">Topic 108812 Version 7.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32032141" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : International Consensus Definition of Low Anterior Resection Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34296335" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The incidence and risk factors of low anterior resection syndrome (LARS) after sphincter-preserving surgery of rectal cancer: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25677122" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Bowel function 14 years after preoperative short-course radiotherapy and total mesorectal excision for rectal cancer: report of a multicenter randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27695976" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Long-term functional follow-up after anterior rectal resection for cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29094352" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Anorectal dysfunction after laparoscopic low anterior rectal resection for rectal cancer with and without radiotherapy (manometry study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30553942" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Functional Outcomes and Health-Related Quality of Life After Curative Treatment for Rectal Cancer: A Population-Level Study in England.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30350191" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Effect of Neoadjuvant Systemic Chemotherapy With or Without Chemoradiation on Bowel Function in Rectal Cancer Patients Treated With Total Mesorectal Excision.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34775413" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Functional Outcome of Laparoscopic-Assisted Resection Versus Open Resection of Rectal Cancer: A Secondary Analysis of the Australasian Laparoscopic Cancer of the Rectum Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37461265" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Ileostomy versus colostomy: impact on functional outcomes after total mesorectal excision for rectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15711859" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Denervation of the neorectum as a potential cause of defecatory disorder following low anterior resection for rectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18549894" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Surgical autonomic denervation results in altered colonic motility: an explanation for low anterior resection syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17153440" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Colonic J-pouch decreases bowel frequency by improving the evacuation ratio.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32154585" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Colonic transit in patients after anterior resection: prospective, comparative study using single-photon emission CT/CT scintigraphy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23869468" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A hyperactive postprandial response in the neorectum--the clue to low anterior resection syndrome after total mesorectal excision surgery?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23932153" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Neorectal hyposensitivity after neoadjuvant therapy for rectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18425933" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Reconstructive techniques after rectal resection for rectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9678375" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Endosonographic evidence of injury to the internal anal sphincter after low anterior resection: long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28682965" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Does a Defunctioning Stoma Impair Anorectal Function After Low Anterior Resection of the Rectum for Cancer? A 12-Year Follow-up of a Randomized Multicenter Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22504191" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Low anterior resection syndrome score: development and validation of a symptom-based scoring system for bowel dysfunction after low anterior resection for rectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27796496" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Clinical application of the LARS score: results from a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31082911" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Normative Data for the Low Anterior Resection Syndrome Score (LARS Score).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15868235" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The development of a validated instrument to evaluate bowel function after sphincter-preserving surgery for rectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37012144" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Systematic review and meta-analysis of randomized clinical trials on the treatment of low anterior resection syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33411977" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Management guidelines for low anterior resection syndrome - the MANUEL project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35412697" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Interprofessional perspectives on care for patients with low anterior resection syndrome: A qualitative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25083060" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Recent advances in pharmacological treatment of irritable bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12791001" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A comparison of the effect of loperamide in oral or suppository form vs placebo in patients with ileo-anal pouches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7995187" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Loperamide improves anal sphincter function and continence after restorative proctocolectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20109999" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effectiveness and tolerability of colesevelam hydrochloride for bile-acid malabsorption in patients with cancer: a retrospective chart review and patient questionnaire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19879973" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33982068" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Anterior resection syndrome: a randomized clinical trial of a 5-HT3 receptor antagonist (ramosetron) in male patients with rectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15316000" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22571474" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Clinical trial assessing VSL#3 for the treatment of anterior resection syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21689359" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Transanal irrigation improves quality of life in patients with low anterior resection syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37160596" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Transanal irrigation in functional bowel disorders and LARS: short-term results from an Italian national study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35797618" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A Randomized Controlled Clinical Trial of Transanal Irrigation Versus Conservative Treatment in Patients With Low Anterior Resection Syndrome After Rectal Cancer Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30083782" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Role of transanal irrigation in the treatment of anterior resection syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26573811" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Global audit on bowel perforations related to transanal irrigation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29722725" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Antegrade Enema After Total Mesorectal Excision for Rectal Cancer: The Last Chance to Avoid Definitive Colostomy for Refractory Low Anterior Resection Syndrome and Fecal Incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18452041" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Rehabilitation of fecal incontinence after sphincter-saving surgery for rectal cancer: encouraging results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25156929" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Pelvic floor muscle training for bowel dysfunction following colorectal cancer surgery: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21940307" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Rehabilitation exercise on the quality of life in anal sphincter-preserving surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22268662" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Functional disorders after rectal cancer resection: does a rehabilitation programme improve anal continence and quality of life?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21825890" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Effectiveness of biofeedback therapy in the treatment of anterior resection syndrome after rectal cancer surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35894434" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The Role of Pelvic Floor Muscle Training on Low Anterior Resection Syndrome: A Multicenter Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16165701" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Prospective comparison of short- and long-term effects of pelvic floor exercise/biofeedback training in patients with fecal incontinence after surgery plus irradiation versus surgery alone for colorectal cancer: clinical, functional and endoscopic/endosonographic findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24037562" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Systematic review of the clinical effectiveness of neuromodulation in the treatment of faecal incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18412293" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Sacral nerve stimulation for faecal incontinence alters colorectal transport.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19712111" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Rectal motility after sacral nerve stimulation for faecal incontinence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12355221" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Bilateral sacral spinal nerve stimulation for fecal incontinence after low anterior rectum resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15785890" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Sacral neuromodulation in treatment of fecal incontinence following anterior resection and chemoradiation for rectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15843939" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Sacral nerve stimulation for faecal incontinence following a rectosigmoid resection for colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17509049" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Sacral neuromodulation in patients with faecal incontinence: results of the first 100 permanent implantations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18278538" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Sacral nerve stimulation in patients after rectal resection--preliminary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19843119" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Sacral nerve stimulation for the treatment of faecal incontinence following low anterior resection for rectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22527919" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Sacral nerve stimulation in patients with severe fecal incontinence after rectal resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23559414" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Sacral neuromodulation for fecal incontinence and "low anterior resection syndrome" following neoadjuvant therapy for rectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25846836" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A systematic review of sacral nerve stimulation for low anterior resection syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33793754" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Percutaneous tibial nerve stimulation in patients with severe low anterior resection syndrome: randomized clinical trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
